Aktuellt
SENASTE
Redeye notes that Egetis’ Q3 report presented SEK12.2m in revenues and SEK-98.8m in operating expenses, which was more or less in line with expectations, albeit with a slightly higher OPEX than anticipated (SEK89m), mainly indicating a quarter of high activity in preparation for the future Emcitate launch, regulatory filing and also reflecting the started ReTRIAC trial with Emcitate. After the quarter, Egetis secured significant financing through a private placement and debt financing– a significant catalyst we argue. We don’t expect to make any significant adjustments to our valuation and will soon return with a more extensive take.
LÄS MER
